$NYMX News Sapient surges on Publicis buyout: Big U.S.

New Post Public Reply Private Reply Replies (0) Message Board

Nov 3, 2014 at 1:27 PM

$NYMX News

Sapient surges on Publicis buyout: Big U.S. stock movers 9:11 a.m. Today - MarketWatch
Friday’s biggest advancers & decliners 5:40 p.m. Dec. 17, 2010 - Kate Gibson
Seven technically strong stocks to buy on a dip 11:15 a.m. May 2, 2007 - Harry Boxer
Nymox: NX-1207 drug has attracted 'serious' interest 1:39 p.m. Jan. 31, 2007 - Gabriel Madway
Nymox: NX-1207 drug has attracted 'serious' interest 1:35 p.m. Jan. 31, 2007 - Gabriel Madway
Tuesday's biggest stock gainers and decliners 6:30 p.m. Dec. 12, 2006 - MarketWatch
Nymox: Review of NX-1207 trial shows no serious side effects 10:09 a.m. June 27, 2006 - Gabriel Madway
Nymox shares up 4.6% at $2.72 10:01 a.m. June 27, 2006 - Gabriel Madway
Nymox: NX-1207 is treatment for benign prostatic hyperplasia 10:00 a.m. June 27, 2006 - Gabriel Madway
Nymox: All trial subjects have completed dosing 9:56 a.m. June 27, 2006 - Gabriel Madway
Nymox: Review of NX-1207 trial shows no serious side effects 9:55 a.m. June 27, 2006 - Gabriel Madway
Nymox Pharma: Positive results on AlzheimAlert from studies 12:42 p.m. June 15, 2006 - Katherine Hunt
Nymox shares down 4.2% at $2.72 12:25 p.m. June 15, 2006 - Gabriel Madway
Nymox reports positive results from AlzheimAlert studies 12:25 p.m. June 15, 2006 - Gabriel Madway
Nymox inks new contract for Alzheimer's test in Korea 11:49 a.m. June 14, 2006 - Katherine Hunt
Nymox shares up 3c at $2.82 11:43 a.m. June 14, 2006 - Katherine Hunt
Terms of Nymox contract with Kyung Min Meditech undisclosed 11:42 a.m. June 14, 2006 - Katherine Hunt
Nymox inks new contract with Kyung Min Meditech in Korea 11:42 a.m. June 14, 2006 - Katherine Hunt
Nymox inks new contract for Alzheimer's test in Korea 11:41 a.m. June 14, 2006 - Katherine Hunt
Nymox Pharma NX-1207 Phase II trial patient dosing complete 8:53 a.m. June 9, 2006 - Carolyn Pritchard

Ad Comm smacks down Sonacare's HIFU device for prostate cancer 12:53 p.m. Oct. 3, 2014 - Seeking Alpha
Encouraging trial results for Nymox prostate cancer drug candidate 12:37 p.m. Sept. 10, 2014 - Seeking Alpha
Encouraging interim results for BPH drug 1:13 p.m. July 22, 2014 - Seeking Alpha
Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox 6:51 a.m. July 18, 2014 - TheStreet.com
Enrollment complete in second BPH Phase 3 trial 10:29 a.m. July 15, 2014 - Seeking Alpha
Oversold Conditions For Nymox Pharmaceutical (NYMX) 12:05 p.m. April 30, 2014 - TheStreet.com
The good, the bad and the ugly about Nymox's cancer drug trial 10:32 a.m. April 30, 2014 - Seeking Alpha
4 Biotechnology Stocks to Sell Now 4:30 a.m. Jan. 29, 2014 - InvestorPlace.com
Is Nymox The Next Unknown Biotech Turned High Flyer? 3:39 p.m. July 15, 2013 - Seeking Alpha
In Nymox The Next Unknown Biotech Turned High Flyer? 3:39 p.m. July 15, 2013 - Seeking Alpha
Nymox Pharma: Developing A Potential Long-Term Treatment For BPH 3:43 p.m. April 3, 2013 - Seeking Alpha
Good News for Nymox's Pipeline - Analyst Blog 5:25 p.m. March 21, 2013 - Zacks.com
4 Healthcare Stock Stories for Tuesday Investment Wellness 2:54 p.m. March 19, 2013 - Wall St. Cheat Sheet
Market Close: Big Winners & Losers for March 18, 2013 (CHRY, ATOS, NYMX, PRWT, ULTR, AMBO, EFUT, CNET, PTX, LDK) 2:20 p.m. March 18, 2013 - 247WallSt.com
4 Healthcare Stock Stories to Spark Investment Chatter 7:33 p.m. March 5, 2013 - Wall St. Cheat Sheet
Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer 11:02 a.m. March 5, 2013 - 247WallSt.com
11 Must Read Weekend Stock Stories For Monday 11:55 a.m. March 2, 2013 - 247WallSt.com
Hot Stocks: Ten Super Crazy Volume Spikes 1:08 p.m. March 1, 2013 - 247WallSt.com
4 Healthcare Stock Stories for Tuesday Wellness 3:45 p.m. Feb. 19, 2013 - Wall St. Cheat Sheet
8 Biotechnology Stocks to Sell Now 4:00 a.m. Jan. 16, 2013 - InvestorPlace.com

Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints 12:01 p.m. Nov. 2, 2014 - GlobeNewswire
Nymox Announces Positive Prostate Cancer 8 Month Clinical Trial Results 8:31 a.m. Sept. 10, 2014 - GlobeNewswire
Nymox Reports Second Quarter 2014 Financial Results 8:31 a.m. Aug. 11, 2014 - GlobeNewswire
Press Release Issued Under the Early Warning System/Sale of Shares of Nymox Pharmaceutical Corporation 4:01 p.m. Aug. 6, 2014 - GlobeNewswire
Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH 8:30 a.m. July 22, 2014 - GlobeNewswire
Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study 8:30 a.m. July 15, 2014 - GlobeNewswire
Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 9:01 a.m. June 17, 2014 - GlobeNewswire
Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug 9:16 a.m. June 11, 2014 - GlobeNewswire
Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment 8:51 a.m. May 21, 2014 - GlobeNewswire
Nymox Reports First Quarter 2014 Financial Results 8:46 a.m. May 15, 2014 - GlobeNewswire
Nymox Pharmaceutical Late- Stage Clinical Trials Substantiating Investor Interest; Analyst Report by BrokerBank Securities, Inc. 6:00 a.m. May 14, 2014 - PR Newswire - PRF
Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels 8:46 a.m. May 13, 2014 - GlobeNewswire
Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH 9:31 a.m. May 8, 2014 - GlobeNewswire
Nymox Announces Positive New Prostate Cancer Clinical Trial Results 9:01 a.m. May 6, 2014 - GlobeNewswire
Nymox Reports Top-Line Results for Localized Prostate Cancer Study 8:32 a.m. April 30, 2014 - GlobeNewswire
Nymox Reports 2013 Financial Results 12:00 p.m. March 14, 2014 - GlobeNewswire
Nymox Announces Appointment of Andre Monette 2:00 p.m. Feb. 5, 2014 - GlobeNewswire
Nymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities 11:30 a.m. Jan. 28, 2014 - GlobeNewswire
Nymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial 10:00 a.m. Jan. 13, 2014 - GlobeNewswire
Madison Capital Corporation Announces Proposed Qualifying Transaction 12:36 p.m. Nov. 21, 2013 - Marketwire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Machine Grabs Prime Dallas Property Amid Apartment Boom

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....